Safety and efficacy of autologous cell vaccines in solid tumors : a systematic review and meta-analysis of randomized control trials
© 2023. The Author(s)..
We conducted a systematic review and meta-analysis of randomized control trials to formally assess the safety and efficacy of autologous whole cell vaccines as immunotherapies for solid tumors. Our primary safety outcome was number, and grade of adverse events. Our primary efficacy outcome was clinical responses. Secondary outcomes included survival metrics and correlative immune assays. We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for studies published between 1946 and August 2020 using any autologous whole cell product in the treatment of any solid tumor. The Cochrane Randomized Controlled Trial risk of bias tool was used to assess risk of bias. Eighteen manuscripts were identified with a total of 714 patients enrolled in control and 808 in vaccine arms. In 698 patients receiving at least one dose of vaccine, treatment was well tolerated with a total of 5 grade III or higher adverse events. Clinical response was reported in a minority (n = 2, 14%) of studies. Autologous cell vaccines were associated with improved overall (HR 1.28, 95% CI 1.01-1.63) and disease-free survival (HR 1.33, 95% CI 1.05-1.67) over thirteen and ten trials respectively. Where reported, immune assays correlated well with clinical outcomes. Our results suggest that autologous whole cell vaccination is safe and efficacious in increasing survival in patients undergoing treatment for solid tumors.Registration: PROSPERO CRD42019140187.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Scientific reports - 13(2023), 1 vom: 27. Feb., Seite 3347 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bastin, Donald J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer Vaccines |
|---|
| Anmerkungen: |
Date Completed 01.03.2023 Date Revised 12.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-023-29630-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353558931 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353558931 | ||
| 003 | DE-627 | ||
| 005 | 20240312233003.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-023-29630-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM353558931 | ||
| 035 | |a (NLM)36849805 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bastin, Donald J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and efficacy of autologous cell vaccines in solid tumors |b a systematic review and meta-analysis of randomized control trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.03.2023 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a We conducted a systematic review and meta-analysis of randomized control trials to formally assess the safety and efficacy of autologous whole cell vaccines as immunotherapies for solid tumors. Our primary safety outcome was number, and grade of adverse events. Our primary efficacy outcome was clinical responses. Secondary outcomes included survival metrics and correlative immune assays. We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for studies published between 1946 and August 2020 using any autologous whole cell product in the treatment of any solid tumor. The Cochrane Randomized Controlled Trial risk of bias tool was used to assess risk of bias. Eighteen manuscripts were identified with a total of 714 patients enrolled in control and 808 in vaccine arms. In 698 patients receiving at least one dose of vaccine, treatment was well tolerated with a total of 5 grade III or higher adverse events. Clinical response was reported in a minority (n = 2, 14%) of studies. Autologous cell vaccines were associated with improved overall (HR 1.28, 95% CI 1.01-1.63) and disease-free survival (HR 1.33, 95% CI 1.05-1.67) over thirteen and ten trials respectively. Where reported, immune assays correlated well with clinical outcomes. Our results suggest that autologous whole cell vaccination is safe and efficacious in increasing survival in patients undergoing treatment for solid tumors.Registration: PROSPERO CRD42019140187 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Systematic Review | |
| 650 | 7 | |a Cancer Vaccines |2 NLM | |
| 700 | 1 | |a Montroy, Joshua |e verfasserin |4 aut | |
| 700 | 1 | |a Kennedy, Michael A |e verfasserin |4 aut | |
| 700 | 1 | |a Martel, Andre B |e verfasserin |4 aut | |
| 700 | 1 | |a Shorr, Risa |e verfasserin |4 aut | |
| 700 | 1 | |a Ghiasi, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Boucher, Dominique M |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Boaz |e verfasserin |4 aut | |
| 700 | 1 | |a Gresham, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Diallo, Jean-Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Fergusson, Dean A |e verfasserin |4 aut | |
| 700 | 1 | |a Lalu, Manoj M |e verfasserin |4 aut | |
| 700 | 1 | |a Kekre, Natasha |e verfasserin |4 aut | |
| 700 | 1 | |a Auer, Rebecca C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 13(2023), 1 vom: 27. Feb., Seite 3347 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:1 |g day:27 |g month:02 |g pages:3347 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-023-29630-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 1 |b 27 |c 02 |h 3347 | ||